Navigation Links
Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
Date:5/15/2008

BONITA SPRINGS, Fla., May 15 /PRNewswire/ -- Tigris Pharmaceuticals, Inc. announced today the execution of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on clinical and preclinical development of AFP-464, an aminoflavone currently in Phase I development. AFP-464 is converted to metabolites which bind covalently to DNA, resulting in p53 activation and apoptosis.

This is part of a four-year CRADA encompassing multiple Phase I and Phase II clinical studies with correlating translational research of AFP-464 in a variety of tumor types. The goal of this research collaboration is to work together for the successful development of AFP-464 as a safe and effective novel pharmaceutical compound for the treatment of cancer. Under this CRADA, two Phase I studies with AFP-464 are currently enrolling in the United States, sponsored by the NCI, at the Mayo Clinic, Wayne State University, and the University of Maryland. These studies are evaluating AFP-464 in patients with advanced solid tumors. Tigris has also initiated a Phase I program at leading cancer research centers in Belgium and France; this work is not included in the CRADA research. The AFP-464 program is anticipated to move to Phase II development in 2009.

"It will be a privilege to work with the NCI on such a promising therapeutic for patients with cancer," stated Edmundo Muniz, M.D., Ph.D., Chief Executive Officer of Tigris. "This CRADA further solidifies the successful partnership to date between Tigris and the NCI."

About AFP-464

Preclinical studies into AFP-464's mechanism of action have shown that AFP-464 induces CYP1A1/1A2 and CYP1B1 protein expression and is converted to metabolites that are covalently bound to DNA, resulting in phosphorylation of p53 with induction of the p53 downstream target p21(Waf1/Cip1) and apoptosis. AFP-464 has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor ce
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
2. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
3. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
10. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
11. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 ... the addition of the "Endoscopy Global Market ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... approximately $43 billion by 2019 growing at around ... drivers for the market growth are aging population, ...
(Date:4/27/2015)... April 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced ... of lonafarnib in patients with chronic hepatitis delta viral ... program, enrolled at Ankara University Medical School, ... endemic. LOWR HDV - 1 (LOnafarnib ... study which randomized subjects to receive different doses of ...
(Date:4/27/2015)... di Reggio Emilia, the Regional Health Service office for ... Zebra Technologies Corporation (NASDAQ: ZBRA ) wireless ... (WNS) provided by Zebra has allowed staff to ... via mobile computers, contributing to improved patient care with ... and guest Wi-Fi access and enables hospital staff to ...
Breaking Medicine Technology:Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 2Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 3Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 4Zebra Technologies' Wireless Solutions Help Reggio Emilia Hospital Staff Improve Patient Care and Reduce Costs 5
... Corporation (NYSE: SGP ) today reported that interim ... (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent ... virus (HCV) genotype 1. In the lead-in arms ... lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) ...
... Sciences, Inc. (Nasdaq: CALP ), a leading provider of ... from the United States Food and Drug Administration (FDA) on ... screening and characterization assays for biological drugs. , "We were ... platform to a large group of reviewers. We believe the ...
Cached Medicine Technology:Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2
(Date:4/27/2015)... Clyde, NC (PRWEB) April 27, 2015 ... residents will conclude a social media campaign to raise ... and developer, Michael Mamas; and Sri Somesvara Temple. Ironically, ... Ridge Mountains of North Carolina, they thought they were ... commit to at least six months of meditation, service ...
(Date:4/27/2015)... 2015 Telematics Berlin is Europe’s biggest ... associations, CE players and the government to discuss the ... the car. This year’s panel on connected car security ... European Commission, is an opportunity to hear and contribute ... European Automotive Security Standard for years to come. ...
(Date:4/27/2015)... Chicago and its seven surrounding counties ... make area communities healthier, more sustainable and more beautiful. ... every five parkway trees likely to soon be destroyed ... this tree “tipping point,” Chicago-area residents are concerned, as ... Morton Arboretum . The Lisle, Illinois-based tree-focused institution’s Talking ...
(Date:4/27/2015)... The global coagulation analyzers market is estimated to ... however, it is expected to witness high growth ... Brazil in the next five years. Growth in ... such as increasing adoption of automated hemostasis instruments ... developments in high-sensitivity point-of-care coagulation analyzers and introduction ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The Mount ... a seamless referral process for the Health System’s care ... heart failure or diabetes, for instance, may have more ... physicians coordinate with many other care providers. With medical ... of thousands of patients each year, the need for ...
Breaking Medicine News(10 mins):Health News:Mount Soma Monks Do Social Media 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 2Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 3Health News:New Study from The Morton Arboretum Reveals Chicagoans' Take on Trees 4Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 2Health News:Coagulation Analyzers Market Concluded to Reach $3.58 billion by 2019 3Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... A new study shows obesity may increase the risk ... by researchers at the National Institutes of Health, reveals ... adenocarcinoma than with squamous cell carcinoma. ,The study ... carcinoma, and 307 women without cancer as the control ...
... year, about 12,000 cases of cancer of the larynx are ... will have to have a laryngectomy// - taking away their ... new alternative that's giving patients their voices back. ,For ... no voice. "Some things you do not forget, and that ...
... to prevent bone loss may also help prevent prostate cancer ... United Kingdom indicates oral sodium clodronate may slow the spread ... death. //This is a drug commonly used to prevent bone ... in about 85 percent of men. The researchers recruited 311 ...
... done previously have shown that the hormone could suppress ... would not work in obese people because studies of another ... do a second trial to see if obese people were ... they are. They're just as sensitive as thin people." ...
... to eat healthier. A new study finds whole grains, fruits ... your overall risk of dying. However, the study also reports ... stroke. ,The U.S. Dietary Guidelines for Americans include choosing ... variety of grains daily, especially whole grains. While at least ...
... who suffer from asthma do not meet the right ... activity// of adults with asthma. Knowing if asthma patients ... health professionals in designing fitness programs for asthma patients. ... Prevention conducted a study to look at the physical ...
Cached Medicine News:Health News:A voice saving surgery 2Health News:Extra hormone found to cut appetite by a third 2
... compact system provides an ideal solution ... the laboratory, satellite lab and the ... staining method with wedge-smear technology, the ... standardization in a safe enclosed environment. ...
It is a cardio-pulmonary exercise testing device....
... Q-Stress Treadmill has digitally-controlled drive ... moving parts that can wear out. ... speed change mechanism, and fewer drive ... level of dependability. It can carry ...
... feature our internationally-acclaimed algorithm that is ... has a proven record for reliability ... and it's just one of several ... market leader in the stress testing ...
Medicine Products: